Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single IV Dose of Olorofim in Healthy Subjects
NCT03076905Phase 1Withdrawn
- Sponsor
- F2G
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of olorofim in invasive aspergillosis (IA), sponsored by F2G. Primary endpoint: Area Under the Curve from time zero to the last measurable concentration at 120 hours. Planned start May 2017; status: withdrawn.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT03076905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03076905.